

Prostatype® publishes update on concrete commercial progress in Spain

Prostatype Genomics AB ("Prostatype Genomics" or "the Company") announces concrete commercial progress in Spain following the presentation of positive data from a Spanish multicentre study with the genetic test Prostatype® in April. Agreements have so far been signed with around ten private healthcare providers in the country, of which some have started using the test commercially, and negotiations are ongoing with over ten university hospitals and additional private healthcare providers.

The Company and Eurofins Megalab, the Company's distributor in the region, expect that agreements with university hospitals will be able to be signed in the coming quarters as they secure budgeted funds for use of the product.

"We are now experiencing a commercial snowball effect in Spain after the presentation of positive results from the Spanish multicentre study with Prostatype®. It is clear that many Spanish healthcare providers have been impressed by the significant gains in quality of life for patients and reduced healthcare costs that Prostatype® can bring about, and they now want to get started with the clinical use. This is very positive news for Spanish prostate cancer patients, while we at the same time expect a significant, gradual scale-up of our sales in Spain in the coming quarters," says Prostatype Genomics' CEO Fredrik Rickman.

About the results from the Spanish multicentre study

The results from the multicentre study in Spain, which was conducted at seven leading Spanish hospitals under the coordination of the Spanish National Association of Urology, showed that the treatment plan could have been modified for as many as 39% of the patients if Prostatype® had been used as a decision-making basis for choosing the form of treatment when prostate cancer was diagnosed. In a significant percentage of these cases, surgery or radiation, often associated with lifelong side effects for the patient, could have been avoided. Read more about the study in [the press release published on April 16](#).

The results from the multicentre study were presented in April 2024 at the annual conference of the Spanish National Association of Urology. Prostatype® was highlighted at this conference with, among other things, a dedicated panel debate. Read more about this in [the Company's latest newsletter](#).

For more information, please contact:

Fredrik Rickman, CEO Prostatype Genomics AB

Telephone: +46 (0)73 049 77 01

Email: fredrik.rickman@prostatypegenomics.com

About Prostatype Genomics AB

Prostatype® is a genomic test that is available to patients and treating urologists as a complementary decision basis for the question of treatment or no-treatment of prostate cancer. The test was developed by a leading research group at Karolinska Institute and is provided by Prostatype Genomics AB.

